MX2013000744A
(es)
|
2010-07-22 |
2013-03-07 |
Gilead Sciences Inc |
Metodos y compuestos para tratar infecciones virales por paramyxoviridae.
|
WO2015113990A1
(en)
*
|
2014-01-30 |
2015-08-06 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
CA2948080A1
(en)
*
|
2014-05-13 |
2015-11-19 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
TWI767201B
(zh)
|
2014-10-29 |
2022-06-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
EP3256471B1
(en)
*
|
2015-02-11 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
JP6462155B2
(ja)
|
2015-05-04 |
2019-01-30 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎ウイルス感染症の治療用のHBsAg(HBV表面抗原)及びHBV DNA産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
WO2016183266A1
(en)
|
2015-05-13 |
2016-11-17 |
Enanta Pharmaceuticals, Inc. |
Ehpatitis b antiviral agents
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
JP6598974B2
(ja)
|
2015-07-21 |
2019-10-30 |
エフ.ホフマン−ラ ロシュ アーゲー |
B型肝炎ウイルス感染症の治療および予防のための新規な三環式4−ピリドン−3−カルボン酸誘導体
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
CN107820496B
(zh)
*
|
2015-07-27 |
2020-11-03 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的四环4-氧代-吡啶-3-甲酸衍生物
|
WO2017017043A1
(en)
*
|
2015-07-28 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
|
MA42819A
(fr)
|
2015-09-16 |
2018-07-25 |
Gilead Sciences Inc |
Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
|
WO2017102648A1
(en)
*
|
2015-12-15 |
2017-06-22 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
|
WO2017108630A1
(en)
*
|
2015-12-21 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
|
WO2017114812A1
(en)
*
|
2015-12-29 |
2017-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an interferon
|
EA038098B1
(ru)
|
2016-02-19 |
2021-07-06 |
Новартис Аг |
Тетрациклические пиридоновые соединения в качестве противовирусных средств
|
ES2938341T3
(es)
|
2016-03-07 |
2023-04-10 |
Enanta Pharm Inc |
Agentes antivirales contra la hepatitis B
|
CN109414508A
(zh)
|
2016-05-27 |
2019-03-01 |
吉利德科学公司 |
使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
WO2017211791A1
(en)
|
2016-06-07 |
2017-12-14 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a tlr7 agonist
|
EP3468561A4
(en)
|
2016-06-10 |
2019-12-04 |
Enanta Pharmaceuticals, Inc. |
ANTIVIRAL AGENTS AGAINST HEPATITIS B
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
CN110156774A
(zh)
|
2016-07-29 |
2019-08-23 |
新波制药有限公司 |
用于治疗hbv感染的新颖治疗剂
|
WO2018019297A1
(zh)
*
|
2016-07-29 |
2018-02-01 |
银杏树药业(苏州)有限公司 |
异喹啉酮类化合物及其制备抗病毒药物的应用
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
WO2018041873A1
(en)
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
CN109923106B
(zh)
|
2016-09-02 |
2022-09-13 |
吉利德科学公司 |
toll样受体调节剂化合物
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
CR20190181A
(es)
|
2016-10-14 |
2019-08-21 |
Prec Biosciences Inc |
Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
CN110088103B
(zh)
|
2016-11-03 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶化合物
|
EP3535256B1
(en)
|
2016-11-03 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Novel tetrahydroisoquinolines and terahydronaphthyridines for the treatment and prophylaxis of hepatitis b virus infection
|
CN110088104B
(zh)
|
2016-11-03 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物
|
EP3534903B1
(en)
|
2016-11-07 |
2022-08-03 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
CN109369640B
(zh)
*
|
2017-01-13 |
2020-03-27 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物的制备方法
|
TW202402300A
(zh)
|
2017-01-31 |
2024-01-16 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
WO2018154466A1
(en)
*
|
2017-02-21 |
2018-08-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dihydroquinolizinones as antivirals
|
CN106928215B
(zh)
*
|
2017-03-06 |
2019-03-22 |
河南春风医药科技有限公司 |
一种喹嗪酮类化合物的制备方法
|
HUE055170T2
(hu)
*
|
2017-03-09 |
2021-11-29 |
Fujian Cosunter Pharmaceutical Co Ltd |
Hepatitis-B vírus felszíni antigén inhibitor
|
TW201836615A
(zh)
|
2017-03-14 |
2018-10-16 |
美商基利科學股份有限公司 |
治療貓冠狀病毒感染之方法
|
EP3601216B1
(en)
|
2017-03-21 |
2023-10-25 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
AU2018262501B2
(en)
|
2017-05-01 |
2020-12-10 |
Gilead Sciences, Inc. |
Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
US20200197409A1
(en)
*
|
2017-05-22 |
2020-06-25 |
Fujian Cosunter Pharmaceutical Co., Ltd. |
Hepatitis b virus surface antigen inhibitor
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
CN108976223B
(zh)
*
|
2017-06-01 |
2020-08-07 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
CN110066278B
(zh)
*
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
US10675296B2
(en)
|
2017-07-11 |
2020-06-09 |
Gilead Sciences, Inc. |
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
|
WO2019046271A1
(en)
|
2017-08-28 |
2019-03-07 |
Enanta Pharmaceuticals, Inc. |
ANTIVIRAL AGENTS AGAINST HEPATITIS B
|
WO2019065794A1
(ja)
|
2017-09-27 |
2019-04-04 |
国立大学法人鹿児島大学 |
Pac1受容体拮抗薬を用いた鎮痛薬
|
HUE061380T2
(hu)
*
|
2017-10-05 |
2023-06-28 |
Glaxosmithkline Ip Dev Ltd |
Kémiai vegyületek
|
MX2020003464A
(es)
|
2017-10-16 |
2020-08-03 |
Hoffmann La Roche |
Molecula de acidos nucleicos para la reduccion del arnm de papd5 y papd7 en el tratamiento de la infeccion de la hepatitis b.
|
EP3710455A1
(en)
|
2017-11-17 |
2020-09-23 |
Novartis AG |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
EP3694856B1
(en)
*
|
2017-11-22 |
2023-10-25 |
Sunshine Lake Pharma Co., Ltd. |
Fused tricyclic compounds and uses thereof in medicine
|
GB201720163D0
(en)
*
|
2017-12-04 |
2018-01-17 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
|
WO2019113175A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
US10428070B2
(en)
|
2017-12-06 |
2019-10-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
CA3084582A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
WO2019123340A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
CN111433210A
(zh)
|
2017-12-20 |
2020-07-17 |
诺华股份有限公司 |
作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
|
BR112020012518A2
(pt)
*
|
2017-12-22 |
2020-11-24 |
Bayer Aktiengesellschaft |
hidroxi-isoxazolinas e derivados das mesmas
|
CN111511739B
(zh)
*
|
2017-12-28 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的二氢嘧啶基噻唑
|
WO2019143902A2
(en)
*
|
2018-01-22 |
2019-07-25 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
CA3091015C
(en)
|
2018-02-13 |
2023-02-21 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
US10836769B2
(en)
|
2018-02-26 |
2020-11-17 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
WO2019169539A1
(en)
*
|
2018-03-05 |
2019-09-12 |
Pharmaresources (Shanghai) Co., Ltd. |
Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection
|
TWI801517B
(zh)
|
2018-03-12 |
2023-05-11 |
加拿大商愛彼特生物製藥公司 |
經取代的2-吡啶酮三環化合物、其類似物及其使用方法
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
CA3093888A1
(en)
|
2018-04-06 |
2019-10-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
US11505551B2
(en)
|
2018-04-12 |
2022-11-22 |
Arbutus Biopharma Corporation |
Methods for preparing substituted pyridinone-containing tricyclic compounds
|
US10899735B2
(en)
|
2018-04-19 |
2021-01-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
KR102585973B1
(ko)
|
2018-07-03 |
2023-10-10 |
에프. 호프만-라 로슈 아게 |
타우 발현을 조절하기 위한 올리고뉴클레오티드
|
JP7105359B2
(ja)
|
2018-07-13 |
2022-07-22 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
CA3111792A1
(en)
*
|
2018-09-05 |
2020-03-12 |
Children's Medical Center Corporation |
Papd5 inhibitors and methods of use thereof
|
CN110903284B
(zh)
*
|
2018-09-17 |
2023-05-09 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
MX2021003253A
(es)
|
2018-09-21 |
2021-08-11 |
Enanta Pharm Inc |
Heterociclos funcionalizados como agentes antivirales.
|
CN110950860B
(zh)
*
|
2018-09-26 |
2023-03-31 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
EP3856740A4
(en)
|
2018-09-30 |
2021-12-15 |
Sunshine Lake Pharma Co., Ltd. |
CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
|
WO2020086556A1
(en)
|
2018-10-24 |
2020-04-30 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
CN112969505B
(zh)
|
2018-10-31 |
2023-11-14 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
MX2021005047A
(es)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
|
AU2019385477A1
(en)
|
2018-11-21 |
2021-06-10 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
CN111217811B
(zh)
*
|
2018-11-26 |
2024-01-16 |
广东东阳光药业股份有限公司 |
稠合三环类化合物及其在药物中的应用
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
US20220184081A1
(en)
|
2019-02-27 |
2022-06-16 |
Kagoshima University |
Antipruritic agent using pac1 receptor antagonist
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
CA3129011C
(en)
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
JP7154659B2
(ja)
|
2019-04-30 |
2022-10-18 |
ナンキン ヘポ ファーマシューティカル カンパニー リミテッド |
縮合環含有化合物、その使用及びそれを含む医薬組成物
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
WO2020247444A1
(en)
|
2019-06-03 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
CA3142513A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
WO2021007488A1
(en)
*
|
2019-07-11 |
2021-01-14 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
US11497808B2
(en)
|
2019-09-30 |
2022-11-15 |
Gilead Sciences, Inc. |
HBV vaccines and methods treating HBV
|
CN110724140B
(zh)
*
|
2019-11-04 |
2020-10-20 |
中国医学科学院医药生物技术研究所 |
二氢喹嗪酮羧酸类化合物及其应用
|
EP4069729A1
(en)
|
2019-12-06 |
2022-10-12 |
Precision BioSciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
BR112022012625A2
(pt)
|
2019-12-24 |
2022-09-06 |
Carna Biosciences Inc |
Compostos moduladores de diacilglicerol quinase
|
CN113135937A
(zh)
*
|
2020-01-19 |
2021-07-20 |
广东东阳光药业有限公司 |
稠合四环类化合物及其在药物中的应用
|
TWI789695B
(zh)
|
2020-01-27 |
2023-01-11 |
美商基利科學股份有限公司 |
治療sars cov-2感染之方法
|
TWI785528B
(zh)
|
2020-03-12 |
2022-12-01 |
美商基利科學股份有限公司 |
1’-氰基核苷之製備方法
|
US11802125B2
(en)
|
2020-03-16 |
2023-10-31 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
CN115605493A
(zh)
|
2020-03-20 |
2023-01-13 |
吉利德科学公司(Us) |
4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
|
EP4132651A1
(en)
|
2020-04-06 |
2023-02-15 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
JP7049637B1
(ja)
|
2020-05-08 |
2022-04-07 |
国立大学法人 鹿児島大学 |
Pac1受容体拮抗薬を用いた抗うつ・抗不安薬
|
EP4157272A1
(en)
|
2020-05-29 |
2023-04-05 |
Gilead Sciences, Inc. |
Remdesivir treatment methods
|
BR112022026321A2
(pt)
|
2020-06-24 |
2023-01-17 |
Gilead Sciences Inc |
Análogos de 1'-ciano nucleosídeo e usos dos mesmos
|
KR20230048118A
(ko)
|
2020-08-07 |
2023-04-10 |
길리애드 사이언시즈, 인코포레이티드 |
포스폰아미드 뉴클레오티드 유사체의 프로드러그 및 이의 약학적 용도
|
US11773122B2
(en)
|
2020-08-24 |
2023-10-03 |
Gilead Sciences. Inc. |
Phospholipid compounds and uses thereof
|
US11926645B2
(en)
|
2020-08-27 |
2024-03-12 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
TWI811812B
(zh)
|
2020-10-16 |
2023-08-11 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
CN113440520A
(zh)
*
|
2021-04-12 |
2021-09-28 |
桂林医学院 |
七叶内酯衍生物在制备抗乙型肝炎病毒药物中的应用
|
EP4337223A1
(en)
|
2021-05-13 |
2024-03-20 |
Gilead Sciences, Inc. |
Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
|
US20230000873A1
(en)
|
2021-05-26 |
2023-01-05 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
CN117396478A
(zh)
|
2021-06-23 |
2024-01-12 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
AU2022299051A1
(en)
|
2021-06-23 |
2023-12-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CR20230585A
(es)
|
2021-06-23 |
2024-02-19 |
Gilead Sciences Inc |
Compuestos Moduladores de Diacilglicerol Quinasa.
|
KR20240023628A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
WO2023023527A1
(en)
|
2021-08-18 |
2023-02-23 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
TW202345786A
(zh)
|
2022-03-02 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
TW202400185A
(zh)
|
2022-03-02 |
2024-01-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
US20230382940A1
(en)
|
2022-03-03 |
2023-11-30 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
WO2023168194A1
(en)
|
2022-03-03 |
2023-09-07 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
WO2023239665A1
(en)
|
2022-06-06 |
2023-12-14 |
Gilead Sciences, Inc. |
Methods for treatment of viral infections including sars-cov-2
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
WO2024006461A1
(en)
|
2022-06-30 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|